A life-extending prostate cancer drug will continue to only be available to sufferers who have already undergone chemotherapy, the NHS financial watchdog said.
In final draft guidance reassessing the use in the NHS in England of abiraterone, the National Institute for Health and Care Excellence (Nice) ruled that to extend the availability of the drug was "not cost effective at its current price."
There is "clear evidence" that the use of abiraterone before chemotherapy gives patients "longer healthier lives," according to The Institute of Cancer Research, where the drug was discovered.
Nice's chief executive Sir Andrew Dillion said: "We know how important it is for patient to have the option to delay chemotherapy and its associated side affects, so we are disappointed not to be able to recommend abiraterone for use in this way.
"However, the manufacturer's own economic model demonstrated that the drug does not offer enough benefit to justify its price."
More top news
The National Trust has published a list of 50 things for children to do before they turn 11 and three-quarters, such as climbing a tree.
Osayamen Osawe left England two years ago with little knowledge of where was going but is now ready to prove a big hit at Kaiserslautern.
The Royals singer said her driver was "busting a nut" about having just had a star in his car, unaware of who was now on the back seat.